GLP-1s are helping some women with PMOS ovulate again. The bigger question is why.

If you’ve known it for years as PCOS, there’s been a change.

Polycystic ovary syndrome recently got a new name: polyendocrine metabolic ovarian syndrome, or PMOS. 

And honestly? It was overdue.

Because PCOS was never really about cysts in the way the name made it sound. It’s a complicated hormonal and metabolic condition tangled up with insulin, androgens, ovulation, fertility, weight, skin, hair, and plenty more. The ovaries are only a part of the story. They were never the whole story.

So, yay for a better name.

Unfortunately, a rebrand doesn’t make PMOS any less miserable to live with. I know that personally. I’ve dealt with it too, which is probably why I pay especially close attention when something new starts showing up in the research.

And lately, something has.

Women with PMOS taking GLP-1 medications like semaglutide are losing weight, yes. But some are also getting more regular periods and ovulating again. Researchers are seeing changes in insulin resistance and androgen levels too.¹

Interesting already.

But here’s the part that really caught my attention: Scientists are beginning to ask whether GLP-1 signaling might be affecting the reproductive biology of PMOS itself.

In other words, what if this isn’t all about weight loss?

We don’t know yet. But for once, we have actual research starting to ask the question.

Let’s get into it.

Why PCOS became PMOS

The name change actually tells us a lot about how our understanding of this condition has evolved.

PCOS got its name because doctors saw ovaries filled with lots of small, fluid-filled structures and called them “cysts.”

Except now we know they aren’t really cysts. They’re actually follicles, each one with an immature egg inside. 

In a normal cycle, several follicles start developing, but eventually one takes the lead and becomes the dominant follicle that releases an egg at ovulation.

In PMOS, that process can stall. Instead of one follicle pulling ahead, multiple small follicles can get stuck in development. No dominant follicle means no egg gets released, which is why irregular or absent ovulation is so common.

So the more we learned, the more we realized that the biology behind these stalled follicles was much bigger. 

And it became harder to call this just an ovarian disorder.

PMOS is much more than an ovary problem

PMOS can look really different from one woman to the next — insulin resistance, irregular ovulation, higher androgens, or usually some tangle of all three, depending on who you ask.² 

That variability is one of the reasons this condition can be really frustrating. Two women can have the same diagnosis and have very different symptoms.

So the old name started to feel pretty limiting. 

“Polycystic ovary syndrome” made it sound like this was mainly about cysts on the ovaries, when the biology is much broader than that. 

The new name, polyendocrine metabolic ovarian syndrome, is definitely a mouthful. But it gets much closer to what’s actually going on: hormones, metabolism, and ovarian function are all part of the same conversation.

Why GLP-1s made sense for PMOS in the first place

For a lot of women with PMOS, insulin resistance is a big piece of their biological puzzle. And insulin, as it turns out, has ambitions well beyond blood sugar.

When insulin stays high, it can nudge the ovaries to make more androgens, including testosterone. At the same time, it can lower a protein called sex hormone-binding globulin (SHBG). Think of SHBG as a biochemical sponge of sorts, soaking up some of that testosterone and keeping it out of circulation.

With less SHBG around, more testosterone is left free to do its thing. And too much of it can interfere with ovulation.

So where do GLP-1s come in?

This is where the connection starts to make sense. GLP-1 medications can improve insulin sensitivity and help with weight loss. 

Bring high levels of insulin down, and you may start easing some of the hormonal chaos that comes with it.

That could help explain why some women with PMOS are seeing more regular periods and ovulation return: when insulin and androgens ease up, follicles get a better shot at developing normally instead of stalling out.³

But what if that’s not the whole explanation?

What if GLP-1s are doing something in the ovary itself?

In preclinical studies, researchers have found GLP-1 receptors on granulosa cells, the cells that surround and support a developing egg⁴. These cells have an important job to do. They respond to reproductive hormones and help with follicle growth, basically helping an egg make it to the finish line of ovulation.

So now the question is: Could GLP-1 medications be influencing those granulosa cells directly?

Maybe.

What’s actually happening in the follicle?

In animal and cell studies, GLP-1 signaling seems to help the cells around a developing egg stay healthier and communicate better with the egg itself.

In other words, there are some early signs that GLP-1 signaling could help create a healthier environment for a follicle to keep developing instead of stalling out.⁵

That is a very different idea from simply saying, “She lost weight, her insulin improved, and her period came back.” 

It raises the possibility that GLP-1 signaling may be interacting with the ovary itself.

And I want to be very clear here: We don’t have human clinical trials proving that yet. Most of this direct-ovary evidence comes from cell and animal research, and some preclinical studies have shown different effects depending on the model and dose.

So while we can’t say this is happening in women yet, there’s enough biology here to keep asking the question.

And it doesn’t stop at the ovary

Because apparently the ovary isn’t the only place GLP-1s may be at work.

A 2026 review looked at PMOS through a much broader lens, including the brain.⁶ That makes sense, because the hypothalamus helps coordinate the hormone signals that drive ovulation, and in PMOS, those signals can get out of rhythm.

GLP-1 receptors are active in the brain too, and researchers are exploring whether these medications might influence some of that reproductive signaling, including leptin sensitivity and GnRH-related hormone rhythms.

Very early. Very much unproven.

But it adds one more intriguing possibility: GLP-1s may be affecting PMOS biology at more than one level.

So where does that leave us?

I think there’s real reason to be hopeful here.

For some women with PMOS, GLP-1 medications seem to be doing more than helping with weight loss. We’re seeing improvements in insulin resistance, menstrual regularity, and ovulation, and researchers are starting to uncover biological reasons those changes may be happening.

That’s exciting.

But PMOS is complicated, and we are nowhere near having the whole thing figured out. We still don’t know how much of these reproductive improvements come from weight loss and better insulin control versus direct effects on the ovary or the brain. We also don’t know which women are most likely to benefit.

And GLP-1 medications aren’t something to jump into casually. Nausea and other gastrointestinal side effects are common, and reproductive planning matters because these medications are generally stopped before pregnancy.

So no, I don’t think GLP-1s are the answer to PMOS.

But I do think they’re helping researchers ask better questions about what this condition actually is and why ovulation goes off track in the first place.

And after decades of women being handed the same limited advice over and over?

I’ll take better questions.

Disclaimer: This article is for educational and informational purposes only and isn’t intended to diagnose, treat, cure, or prevent any medical condition or replace individualized medical advice. Always talk with your healthcare provider before starting or changing medications, supplements, hormones, or other treatments.

---

1.  Zhou L, Qu H, Yang L, Shou L. Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review. BMC Endocr Disord. 2023 Nov 8;23(1):245. doi: 10.1186/s12902-023-01500-5. PMID: 37940910; PMCID: PMC10631119. ↩︎
2.  Shukla A, Rasquin LI, Anastasopoulou C. Polyendocrine Metabolic Ovarian Syndrome. [Updated 2025 Jul 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/sites/books/NBK459251/ ↩︎
3. Carmina E, Longo RA. Evidence That Semaglutide Represents an Important Tool for Treatment of Irregular Menses and Chronic Anovulation in Women with Polyendocrine Metabolic Ovarian Syndrome. J Clin Med. 2026 Jul 2;15(13):5165. doi: 10.3390/jcm15135165. PMID: 42452625; PMCID: PMC13362893. ↩︎
4.  Sun Z, Li P, Wang X, Lai S, Qiu H, Chen Z, Hu S, Yao J, Shen J. GLP-1/GLP-1R Signaling Regulates Ovarian PCOS-Associated Granulosa Cells Proliferation and Antiapoptosis by Modification of Forkhead Box Protein O1 Phosphorylation Sites. Int J Endocrinol. 2020 Jun 19;2020:1484321. doi: 10.1155/2020/1484321. PMID: 32655632; PMCID: PMC7321515. ↩︎
5. Zhao M, Liao B, Yun C, Qi X, Pang Y. Liraglutide improves follicle development in polycystic ovary syndrome by inhibiting CXCL10 secretion. Reprod Biol Endocrinol. 2024 Aug 6;22(1):98. doi: 10.1186/s12958-024-01269-9. PMID: 39107809; PMCID: PMC11302332. ↩︎
6.  Xu W, Lu C, Xu J, Wang L. The neuroendocrine-appetite-mental health triangle in PMOS: Implications for GLP-1 receptor agonist therapy. Neurosci Biobehav Rev. 2026 Oct;189:106846. doi: 10.1016/j.neubiorev.2026.106846. Epub 2026 Jul 8. PMID: 42419462. ↩︎